Amunix Pharmaceuticals
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Tower Pl Ste 1100, South San Francisco...Phone Number
(650) 428-1800Website
www.amunix.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Amunix Pharmaceuticals
Amunix Pharmaceuticals, founded in 2006 and headquartered in Mountain View, California, manufactures pharmaceuticals for the cancer industry.Explore more
Amunix Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amunix Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Amunix Pharmaceuticals recently announced quarterly report
Check if Amunix Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Amunix Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Amunix Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Amunix Pharmaceuticals
Website visits: Recent activity has been detected on your website
Click to see if Amunix Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Amunix Pharmaceuticals has new funding data
Amunix Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Amunix Pharmaceuticals
Find more new buyers
Compare Similar Companies to Amunix Pharmaceuticals
Compare insights from companies similar to Amunix Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Amunix Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amunix Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amunix Pharmaceuticals.
Amunix Pharmaceuticals financials insights
Gather financial insights about Amunix Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$73M
2021
Series B
$117M
Amunix Pharmaceuticals Tech Stack
A closer look at the technologies used by Amunix Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Mergers & Acquisitions (M&A)
Mergers & Acquisitions (M&A)
Executive Move
Executive Moves
Amunix Pharmaceuticals News & Media
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment of patients with solid tumors.Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engager and cytokine therapies for patients with cancer, today announced that it has expanded its board of directors with the appointment of Frank Watanabe, CEO of Arcutis and a biopharmaceutical executive with extensive leadership, strategy, opAmunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety
AMX-818 is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated T cell engager) platform designed to improve the toxicity profile of T cell engagers for the treatment of HER2-expressing solid tumorsAmunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, today announced that it has raised $117 million Series B financing. The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amunix Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Amunix Pharmaceuticals, founded in 2006 and headquartered in Mountain View, California, manufactures pharmaceuticals for the cancer industry.... Read More
